Fiscal 2026 Revenue Guidance
Based on current internal planning assumptions, the Company expects fiscal 2026 revenue of approximately $150 million, representing a conservative baseline outlook reflecting currently contracted demand and visible partner activity.¹
This guidance is intended to represent a baseline or "floor-case" scenario and assumes continued execution across the Company's existing pharmacy operations and digital health platform. The guidance excludes any potential incremental contributions from acquisitions, new geographic market entries, or commercial arrangements that are not currently operational as of the date of this release.
Q1 2026 Revenue Outlook
The Company expects revenue to increase throughout fiscal 2026 as several major partnerships, clients, and pharmacy product lines that were planned and implemented in late 2025 and early 2026 go live. Based on current visibility and contracted activity, the Company expects revenue for the first quarter of fiscal 2026 to be in the range of approximately $25 million to $28 million.
Cost Structure, Margin and Profitability Context
The Company's fiscal 2026 guidance assumes no material increase in fixed operating costs relative to late-2025 levels. Hydreight has already established its national regulatory, pharmacy, and technology infrastructure, and management expects incremental revenue growth to be supported largely by this existing cost base.
Based on current internal planning assumptions, and assuming fiscal 2026 revenue of approximately $150 million, management expects the Company to generate an Adjusted EBITDA margin of approximately 15–17%.²
This reflects the anticipated benefit of scaling transaction volumes across a largely fixed operating cost structure. While the Company believes it is well positioned to benefit from operating leverage as revenue grows, actual results may vary based on transaction volumes, partner mix, product utilization, and other operational factors.
Baseline ("Floor-Case") Assumptions
Management defines the $150 million fiscal 2026 guidance as a baseline outlook because it is derived solely from:
Existing partner relationships and currently active customer programs
Observable transaction volumes and contracted demand
Continued utilization of the Company's existing pharmacy and platform infrastructure
The guidance does not assume contributions from potential acquisitions, expansion into new international markets, or additional enterprise partnerships beyond those already in operation as of the date of this release.
Management Commentary
"This guidance reflects the visibility we now have into our operations as we enter 2026," said Shane Madden, Chief Executive Officer of Hydreight. "Importantly, it is grounded in existing demand and supported by a disciplined cost structure. With much of our infrastructure already in place, we believe the business is positioned to scale efficiently while maintaining margin discipline as transaction volumes grow."
Capital Position
The Company recently completed a $15 million bought deal financing led by Canaccord Genuity Corp. The proceeds provide additional working capital to support anticipated transaction volumes and ongoing operations. Management believes the Company is adequately capitalized to execute on its fiscal 2026 baseline outlook.
The Company thanks its partners, healthcare professionals, licensees, and shareholders for their continued support.
On behalf of the Board of DirectorsShane MaddenDirector and Chief Executive OfficerHydreight Technologies Inc.
ContactEmail: [email protected]; Telephone: (702) 970-8112
Hydreight Technologies Inc Ranked Number 56 Fastest-Growing Company in North America on the Deloitte ...
